Piper Sandler cuts Connect Biopharma stock price target on launch delay
Piper Sandler reduced its price target for Connect Biopharma (CNTB) to $5.00 from $7.00, citing a delayed launch timeline for rademikibart. The stock is trading at $0.64, down 74% over the past year. The company reported mixed Phase 2 trial results and plans to discuss Phase 3 programs with the FDA. Analysts have mixed price targets, ranging from $4 to $9.

